Eagle Point Credit Co has announced its intention to redeem certain securities, including its 6.50% Series C Term Preferred Shares and 5.375% notes due 2029. This decision, filed with the Securities and Exchange Commission on November 13, 2026, is significant as it reflects the company's ongoing financial management strategies and may impact investor sentiment in the sector.
Background
Eagle Point Credit Co is a company listed on the New York Stock Exchange under the tickers ECC, ECCC, ECC-PD, ECCU, and ECCV. The company is classified under the investment management sector, focusing on generating income through investments in credit-related assets. Its recent filings indicate a proactive approach to managing its capital structure.
What the Filing Says
The SEC filing indicates that the company intends to redeem all outstanding Series C Term Preferred Shares, totaling 1,766,576 shares, and 25% of its 2029 Notes, amounting to approximately $20,885,375. The redemption date for both securities is set for December 22, 2026. The filing states, "The Company will redeem all of the outstanding Series C Term Preferred Shares... The Company will redeem 25% of the outstanding aggregate principal amount of the 2029 Notes." This move is executed in accordance with the governing instruments of the respective securities.
Impact
This redemption may affect various stakeholders, including current investors in the Series C Term Preferred Shares and 2029 Notes, as well as potential investors observing the company's financial maneuvers. It could also influence the broader investment management industry, prompting competitors to evaluate their own capital strategies in response.
What's Next
The filing does not say what happens next.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










